Romero-Romero Beatriz, Botana-Rial Maribel, Martínez Raquel, Elias-Hernandez Teresa, Rodrigues-Gómez Ricardo M, Valdivia M Mar
Pulmonary Department, Hospital Universitario Vírgen del Rocío, Sevilla, Spain.
Pulmonary Department, Hospital Álvaro Cunqueiro, EOXI Vigo, Spain.
Open Respir Arch. 2025 Feb 27;6(Suppl 2):100420. doi: 10.1016/j.opresp.2025.100420. eCollection 2024 Oct.
Modern management of thoracic disease is dominated by ultrasound assessment with strong evidence supporting its use in many clinical settings, providing both diagnostic and procedural. Thoracic ultrasound is a pivotal step in the management of chronic lung disease and pulmonary vascular disease, in early assessment as in therapeutic monitoring. Development and validation of novel ultrasound biomarkers of activity and prognostic, especially those linked to advanced ultrasound techniques, are expected in the coming years. Assessing and treating respiratory muscle dysfunction is crucial for patients with both acute and chronic respiratory failure. To explore novel techniques, including imaging with ultrasound is important. Artificial intelligence (AI) excels at automatically recognizing complex patterns and providing quantitative assessment for imaging data, showing high potential to assist physicians in acquiring more accurate and reproducible results. Finally, a training system with structured proficiency and competency standards, about the use of TU is necessary. We offer our perspective on the challenges and opportunities for the clinical practice in other scenarios.
现代胸科疾病管理以超声评估为主导,有强有力的证据支持其在许多临床环境中的应用,兼具诊断和操作功能。胸部超声是慢性肺病和肺血管疾病管理中的关键步骤,无论是早期评估还是治疗监测。预计未来几年将开发和验证新型的活动和预后超声生物标志物,尤其是那些与先进超声技术相关的标志物。评估和治疗呼吸肌功能障碍对急性和慢性呼吸衰竭患者至关重要。探索新技术,包括超声成像很重要。人工智能擅长自动识别复杂模式并为成像数据提供定量评估,在协助医生获得更准确和可重复的结果方面显示出巨大潜力。最后,需要一个关于经胸超声使用的具有结构化熟练程度和能力标准的培训系统。我们对其他场景下临床实践的挑战和机遇发表我们的看法。